Form 4: Karyopharm Therapeutics CEO Richard Paulson Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Richard Paulson, CEO of Karyopharm Therapeutics, sold 4,055 shares of common stock to cover withholding tax liabilities incurred upon the vesting of restricted stock units.
Summary
- Richard A. Paulson, the President and CEO of Karyopharm Therapeutics Inc., sold 4,055 shares of common stock on January 6, 2025.
- The sale was executed at a price of $0.783 per share.
- The transaction was conducted under a pre-arranged automatic sale plan adopted on June 10, 2021, to cover withholding tax obligations related to the vesting of restricted stock units.
- Following the transaction, Paulson directly owns 1,124,257 shares of Karyopharm Therapeutics Inc.
Sentiment
Score: 6
Explanation: The document is a routine SEC filing related to an executive's stock sale for tax purposes. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations are a routine part of executive compensation and are not necessarily indicative of a negative outlook on the company.
Key Dates
| Date | Description |
|---|---|
| June 10, 2021 | Date of adoption of the durable automatic sale instruction plan. |
| January 6, 2025 | Date of the stock sale transaction. |
| January 7, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.